Biogen Inc (BIIB)

271.20 +1.40  +0.52% NASDAQ Jul 7, 13:42 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
07/23/2020 08:00 EDT Misc Biogen Inc Second Quarter Earnings Conference Call in 2020
07/23/2020 Earnings Biogen Inc Second Quarter Earnings in 2020 Release
06/03/2020 09:00 EDT Misc Biogen Inc Annual General Meeting for 2019
04/22/2020 08:00 EDT Misc Biogen Inc First Quarter Earnings Conference Call for 2020
04/22/2020 Earnings Biogen Inc First Quarter Earnings Result for 2020
02/06/2020 Misc Biogen Inc Annual Report for 2019
01/30/2020 08:00 EST Misc Biogen Inc Fourth Quarter Earnings Conference Call for 2019
01/30/2020 Earnings Biogen Inc Fourth Quarter Earnings in 2019 Release
10/22/2019 08:00 EDT Misc Biogen Inc Third Quarter Earnings Conference Call for 2019
10/22/2019 Earnings Biogen Inc Third Quarter Earnings in 2019 Release
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.biogen.com
  • Investor Relations URL: https://www.biogen.com/en_us/investors.html
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Drug Manufacturers - General
  • Equity Style: Large Cap/Value
  • Next Earnings Release: Jul. 23, 2020
  • Last Earnings Release: Apr. 22, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Top Fund Holders

Symbol Name Weighting
LMPFX ClearBridge Aggressive Growth FI 10.44%
HQL Tekla Life Sciences Investors 7.67%
HQH Tekla Healthcare Investors 6.51%
VPMCX Vanguard PRIMECAP Inv 5.47%
VHCOX Vanguard Capital Opportunity Inv 4.74%
BBH VanEck Vectors Biotech ETF 4.33%
VPCCX Vanguard PRIMECAP Core Inv 3.81%
POGRX PRIMECAP Odyssey Growth 3.47%
IBB iShares Nasdaq Biotechnology ETF 3.35%
VGHCX Vanguard Health Care Inv 2.41%
FXH First Trust Health Care AlphaDEX® ETF 1.92%
VHT Vanguard Health Care ETF 1.16%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.